MAPT and Alzheimer disease: Treatment with MW181—a small-molecule inhibitor of p38α MAPK—decreased tau phosphorylation in an hTau transgenic mouse model of AD, significantly increased the expression of synaptic protein synaptophysin, and improved working memory in rodents.